SCHEMBL3778339

SCHEMBL3778339

CCc1c(Cc2ccc(Cl)cc2)c(C)nc2c(Cl)ccc(O)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ENPP2 Q13822 1/20 0.38
ENPP1 P22413 1/20 0.36
EGLN1 Q9GZT9 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALOX5 P09917 2/20 0.34
ALDH1A1 P00352 3/20 0.34
KMT2A Q03164 1/20 0.34
LMNA P02545 1/20 0.34
GAA P10253 1/20 0.34
RAB9A P51151 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CCNE2 O96020 3/20 0.34
CCNE1 P24864 3/20 0.34
CDK2 P24941 3/20 0.34
CCNB2 O95067 2/20 0.34
CDK1 P06493 2/20 0.34
CDK4 P11802 2/20 0.34
CCNB1 P14635 2/20 0.34
CCND1 P24385 2/20 0.34
CCNB3 Q8WWL7 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3775557 0.87 KMT2A (0.40) ENPP2ENPP1EGLN1ALOX5ALDH1A1
SCHEMBL3771921 0.81 CCNE2 (0.39) ALOX5KMT2ALMNACCNE2CCNE1
SCHEMBL3777320 0.79 TDP1 (0.44) EGLN1
SCHEMBL3779500 0.77 LMNA (0.38) SMN1; SMN2ALDH1A1KMT2ALMNAGAA
SCHEMBL534036 0.74 CHRM4 (0.38)
SCHEMBL3777824 0.73 PTGS2 (0.37) ALOX5
SCHEMBL3778746 0.72 TP53 (0.39) ALDH1A1LMNA
SCHEMBL3777905 0.71 AR (0.39) ENPP2ENPP1ALDH1A1KMT2AGAA
SCHEMBL3771013 0.71 EGLN1 (0.39) ENPP2EGLN1ALDH1A1KMT2ALMNA
SCHEMBL3781729 0.69 ALDH1A1 (0.41) SMN1; SMN2ALDH1A1KMT2ALMNAL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1928457-B1 QUINOLINES AND THEIR THERAPEUTIC USE PULMAGEN THERAPEUTICS ASTHMA LTD (GB) 2012-12-12 EP disclosed
US-7858640-B2 Quinolines and their therapeutic use PULMAGEN THERAPEUTICS (ASTHMA) LIMITED (GB) 2010-12-28 US disclosed
US-20090156600-A1 Quinolines and Their Therapeutic Use GB005, INC. 2009-06-18 US disclosed
EP-1928457-A2 QUINOLINES AND THEIR THERAPEUTIC USE Argenta Discovery Limited (GB) 2008-06-11 EP disclosed
WO-2007036743-A2 QUINOLINES AND THEIR THERAPEUTIC USE ARGENTA DISCOVERY LIMITED (GB) 2007-04-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156600-A1 Quinolines and Their Therapeutic Use NR3C1, NR3C2, NR1H3 ENPP2 234/4885ENPP1 2157/4885EGLN1 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.